Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases

Abroad (travel likely)RecruitingPHASE2

Conditions

Minimal Change Disease (MCD) · IgA Nephropathy (IgAN) · Focal Segmental Glomerulosclerosis (FSGS)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Peking University First Hospital, Beijing, Beijing Municipality, China
Contact: Study coordinator (Hong Zhang) · hongzh@bjmu.edu.cn · +8610-83575530
Tianjin Medical University General Hospital, Tianjin, Hebei, China
Contact: Study coordinator (yan jun Jia) · jiajunya@126.com · +86-13821735536

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

Focal Segmental Glomerulosclerosis · Minimal Change Disease · Immunoglobulin A Nephropathy

Abroad (travel likely)RecruitingPHASE2

Los Angeles, United States · Wilmington, United States

NEPTUNE Match Study

Nephrotic Syndrome in Children · Focal Segmental Glomerulosclerosis · Minimal Change Disease

Abroad (travel likely)Recruiting

Atlanta, United States · Chicago, United States

Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease

Focal Segmental Glomerulosclerosis · Minimal Change Disease · FSGS

Abroad (travel likely)Recruiting

Ann Arbor, United States

A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis

Minimal Change Disease (MCD) · Focal Segmental Glomerulosclerosis (FSGS)

Abroad (travel likely)RecruitingPHASE2, PHASE3

Beijing, China